The phase 3 clinical trial of tolebrutinib did not delay disability progression in people with primary progressive MS, and it has not been approved in the USA for non-relapsing secondary progressive MS.
People with relapsing remitting MS can now access injectable Ocrevus® (ocrelizumab) through the Pharmaceutical Benefits Scheme.
An online training program helps healthcare providers feel more confident and skilled in delivering exercise program to people with MS.
Fenebrutinib is a new treatment from the BTK inhibitor class, which aims to target immune cells throughout the body including the brain and spinal cord to treat MS.
ECTRIMS 2025 spotlighted global advances in MS research, diagnosis, treatment, and prevention under the theme ‘A New Era of Precision’.
An international expert workshop has reviewed the complexities in managing MS in older age, finding knowledge gaps and providing recommendations for the field.
